34270-90-1

Usage

Chemical Properties

Brown Oil

Uses

1,5-Diiodo-3-oxopentane (cas# 34270-90-1) is a compound useful in organic synthesis.

Downstream Products

• 850637-12-6 4-acetyl-tetrahydro-pyran-4-carboxylic acid ethyl ester 
• 15980-15-1 1,4-Oxathiane 
• 6339-26-0 4-tosylmorpholine 
• 100-74-3 N-ethylmorpholine; 
• 109-02-4 4-methyl-morpholine 
• 5337-04-2 tetrahydro-4H-pyran-4,4-dicarboxylic acid 
• 5382-77-4 tetrahydro-pyran-4,4-dicarboxylic acid diethyl ester 
• 34529-07-2 3-morpholin-4-yl-phthalic acid dimethyl ester 
• 693-21-0 diethylene glycol dinitrate 
• 124535-82-6 4-Benzenesulfonyl-4-vinyl-tetrahydro-pyran 
• 57207-22-4 (2R,3R,11R,12R)-(+)-(N,N,N',N',N,N,N',N'-octamethyl-1,4,7,10,13,16-hexaoxacyclooctadecane-2,3,11,12-tetracarboxamide) 
• 77027-53-3 (2R,3R,11R,12R,20R,21R)-(+)-N,N,N',N',N,N,N',N',N,N,N',N'-dodecamethyl-1,4,7,10,13,16,19,22,25-nonaoxacycloheptacosane-2,3,11,12,20,21-hexacarboxamide 
• 88877-45-6 C₃₀H₅₀N₂O₉⁽²⁺⁾*2I^(1-) 
• 88877-45-6 C₃₀H₅₀N₂O₉⁽²⁺⁾*2I^(1-) 

Relevant academic research and scientific papers

Indoline derivatives

This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic rings.

CYCLIC REGIMENS UTILIZING INDOLINE DERIVATIVES

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R 1 and R 2 may be single substituents or fused to form spirocyclic rings, in combination with progestins, estrogens, or both. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.